Pentavalent Meningococcal Conjugate vaccine

EuBiologics, with funding from the RIGHT Foundation, is developing an affordable NmCV-5 to provide broad protection against invasive meningococcal disease. A completed Phase I trial in South Korea demonstrated strong immunogenicity and safety, with responses comparable to or better than existing vaccines. Regulatory consultations with KMFDS and WHO PQ are complete, and clinical trial applications for The Gambia and Mali are in progress, with further funding needed for Phase II/III trials. Meningococcal epidemics continue to threaten the Sub-Saharan African Meningitis Belt, and while a first pentavalent vaccine has been prequalified, Gavi support for non-emergency use will not begin until late 2025. EuBiologics aims to become the second supplier of a WHO-prequalified NmCV-5 by 2027, ensuring a secure and competitively priced vaccine supply. With a target price of $1.34–$2.95 per dose, EuNmCV-5 will strengthen global efforts to eliminate meningitis through routine immunization and preventive campaigns.